Table 3.
Mean length of stay on sick leave within the first 5 years of diagnosis by type of treatment
| Treatment | Length of stay on sick leave | Difference in length of stay on sick leave |
|---|---|---|
| Daysa (95% CI) | ||
| Breast-conserving surgery | ||
| + RT | 102 (87–116) | Ref. |
| + RT + ET | 132 (123–141) | 30 (18–44) |
| + CHEMO + RT | 284 (249–324) | 182 (151–218) |
| + CHEMO + RT + ET | 312 (288–338) | 210 (185–239) |
| Mastectomy | ||
| Mastectomy only | 123 (101–144) | Ref. |
| + ET | 144 (129–157) | 21 (3–38) |
| + RT | 176 (145–205) | 53 (37–69) |
| + CHEMO | 303 (264–345) | 180 (148–217) |
| + CHEMO + ET | 329 (305–352) | 206 (180–233) |
| + CHEMO + RT | 368 (324–409) | 245 (209–280) |
| + CHEMO + RT + ET | 397 (372–419) | 274 (246–300) |
ET initiation of endocrine therapy, CHEMO chemotherapy, RT radiotherapy
aEstimates have been predicted holding all of the other variables constant, using the following covariate pattern: age 50–54 years at diagnosis, ER+ tumor, no lymph node involvement, tumor size 1–30 mm, SNB only, period of diagnosis 2009–2012, Stockholm-Gotland region, middle education, no prior sick leave